Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Qun K. Fang is active.

Publication


Featured researches published by Qun K. Fang.


Tetrahedron-asymmetry | 2000

Rapid access to enantiopure bupropion and its major metabolite by stereospecific nucleophilic substitution on an α-ketotriflate

Qun K. Fang; Zhengxu Han; Paul Grover; Donald W. Kessler; Chris H. Senanayake; Stephen A. Wald

Abstract A stereospecific method for the synthesis of enantiopure α-aminoketone from its corresponding α-hydroxy-ketone via the triflate intermediate is discussed. This strategy provides a rapid and efficient route for the preparation of either enantiomer of bupropion and its biologically active hydroxylated metabolite.


Tetrahedron-asymmetry | 1999

First preparation of enantiomerically pure sibutramine and its major metabolite, and determination of their absolute configuration by single crystal X-ray analysis

Qun K. Fang; Chris H. Senanayake; Zhengxu Han; Cynthia Morency; Paul Grover; Robert E Malone; Hal Bulter; Stephen A. Wald; T. Stanley Cameron

Abstract Racemic sibutramine was resolved with dibenzoyl- d -tartaric acid, and the absolute stereochemistry of sibutramine was determined by single crystal X-ray crystallography of its dibenzoyl d -tartrate. The major active metabolite (desmethylsibutramine) was obtained by demethylation of sibutramine with DEAD. Enantiomeric purity of sibutramine was determined by HPLC on an Ultron ES-OVM column.


Tetrahedron Letters | 1998

An efficient and facile synthesis of racemic and optically active fexofenadine

Qun K. Fang; Chris H. Senanayake; H. Scott Wilkinson; Stephen A. Wald; Hui Li

Abstract An efficient and practical method for the synthesis of racemic and optically active (96% ee) fexofenadine is described. The key racemic or optically active lactol intermediate 2 is prepared from readily available tolyl derivative 3 .


Tetrahedron-asymmetry | 2002

First practical synthesis of enantiomerically pure (R)- and (S)-desmethylsibutramine (DMS) and unambiguous determination of their absolute configuration by single-crystal X-ray analysis

Zhengxu Han; Dhileepkumar Krishnamurthy; Derek Pflum; Qun K. Fang; Hal T. Butler; T. Stanley Cameron; Stephen A. Wald; Chris H. Senanayake

A practical synthesis of enantiomerically pure (R)-desmethylsibutramine [(R)-DMS] and (S)-desmethylsibutramine [(S)-DMS] is outlined along with an improved synthesis of racemic desmethylsibutramine. This route was used for kilo-scale production of enantiomerically pure (R)- and (S)-DMS. Racemic desmethylsibutramine was resolved with either (R)- or (S)-mandelic acid, and the absolute stereochemistry of DMS was determined by single X-ray crystallography of its mandelate salt.


Tetrahedron-asymmetry | 2000

Synthesis of enantiomerically pure desmethylzopiclone and determination of its absolute configuration

Yaping Hong; Roger P. Bakale; Qun K. Fang; Tingjian Xiang; Zhengxu Han; Fran X. McConville; Chris H. Senanayake; Stephen A. Wald

Abstract Two synthetic methods have been established for the preparation of enantiomerically pure desmethylzopiclone, a metabolite of zopiclone. In Method A, (S)-desmethylzopiclone was prepared by demethylation of (S)-zopiclone with 1-chloroethyl chloroformate in high yield. Enantiomerically pure zopiclone (>99% ee) was obtained through a highly efficient resolution process in >36% overall yield. In Method B, racemic desmethylzopiclone was resolved with l -N-benzyloxycarbonyl phenylalanine ( l -ZPA) followed by recrystallization in good yield. The absolute stereochemistry of the (+)-enantiomer was first determined to be the (S)-configuration by X-ray crystallography.


Organic Process Research & Development | 1998

Large-Scale Synthesis of Enantio- and Diastereomerically Pure (R,R)-Formoterol†

Robert Hett; Qun K. Fang; Yun Gao; and Stephen A. Wald; Chris H. Senanayake


Archive | 2003

Compositions comprising zopiclone derivatives and methods of making and using the same

Thomas P. Jerussi; Qun K. Fang


Archive | 2001

Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction

Thomas P. Jerussi; Chrisantha H. Senanayake; Qun K. Fang


Archive | 2002

Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites

Chris H. Senanayake; Thomas P. Jerussi; Mark G. Currie; Qun K. Fang; Bob Hsu


Archive | 2001

Methods of treating or preventing weight gain, obesity, and related disorders

Thomas P. Jerussi; Chrisantha H. Senanayake; Qun K. Fang

Collaboration


Dive into the Qun K. Fang's collaboration.

Researchain Logo
Decentralizing Knowledge